

## SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 MAY 2014

### ERRATA

**(1)** This Erratum corrects the entry for **Olanzapine** in the 1 May 2014 Schedule.

The following Note should appear in the Schedule entry for all Olanzapine items. The Note was omitted for items 1024X, 1037N, 1041T, 1042W, 3381Y, 3382B, 3384D, and 3385E.

**Note**

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

**(2)** This Erratum corrects the entry for **Tocilizumab** in the 1 May 2014 Schedule.

The Notes with the heading “TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS” and with the subheadings:

- (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.
- (2) Swapping therapy.
- (3) Baseline measurements to determine response.

are not relevant to the section 100 Highly Specialised Drugs listing of Tocilizumab for systemic juvenile idiopathic arthritis. These Notes do not apply to the PBS availability of items 1423X, 1464C, 1419Q, 1481Y, 1482B and 1476Q.

**(3)** This Erratum corrects the entry for **Amlodipine + Atorvastatin** in the 1 May 2014 Schedule.

Item codes 9053L, 9054M, 9055N, 9056P, 9049G, 9050H, 9051J and 9052K show the listing of the brands Cadivast 10/10, Cadivast 10/20, Cadivast 10/40, Cadivast 10/80, Cadivast 5/10, Cadivast 5/20, Cadivast 5/40 and Cadivast 5/80 respectively.

The entry is incorrect. The listing of these brands did not proceed.